Last week’s negative FDA advisory committee vote may be the final nail in the coffin in the up-and-down registration path of Biogen...
Anavex Life Sciences Corp. (NASDAQ:AVXL) is a company that we’ve looked at on a number of occasions over the past twelve months...
During the middle of last week, Anavex Life Sciences Corp. (NASDAQ:AVXL) bottomed out on a two-day decline that saw it fall from...
Anavex Life Sciences Corp. (NASDAQ:AVXL) is a stock that we cover pretty regularly here at Insider Financial. The company is a biotechnology...
Anavex Life Sciences Corp. (NASDAQ:AVXL) has had a tough final couple of weeks of September. The company has been one of our...
Back on August 15, we published this piece detailing our thoughts on Anavex Life Sciences Corp. (NASDAQ:AVXL). At the time, the company...
Back on August 7, Anavex Life Sciences Corp. (NASDAQ:AVXL) reported fiscal third quarter 2017 financial results. Markets responded to the news pretty...
The small cap biotechnology space has a reputation for being incredibly volatile and – by proxy – incredibly risky for the uninitiated...
Regular readers will know that Anavex Life Sciences Corp. (NASDAQ:AVXL) is one we’ve repeatedly come back to over the last twelve months...
Anavex Life Sciences Corp (NASDAQ:AVXL), the clinical stage biopharmaceutical developing treatments for neurodegenerative and neurodevelopmental diseases, has been recently under the radar...